Fusion Antibodies PLC
LSE:FAB
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
UK |
Fusion Antibodies PLC
LSE:FAB
|
3.2m GBP | -23.8 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
220.9B USD | 14.3 | ||
US |
Danaher Corp
NYSE:DHR
|
182.8B USD | 7.5 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
40.3B USD | 9.9 | ||
US |
Agilent Technologies Inc
NYSE:A
|
40.3B USD | 12.1 | ||
CH |
Lonza Group AG
SIX:LONN
|
37.1B CHF | 15.8 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
55.2T KRW | 30.2 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
26.9B USD | 12.8 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
26.9B USD | 24.2 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
24.9B USD | 11.4 | ||
FR |
Sartorius Stedim Biotech SA
PAR:DIM
|
19B EUR | 18.3 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.